BLUEJAY DIAGNOSTICS INC (BJDX)
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-04
$0.83-1.94%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-04
QuarterlyIQ Insights · BJDX
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -88.6% |
| Our one-year growth estimate | diamond | Not available |
Growth built into the price is above our model estimate.
A comparable growth gap is not available.
The one-year revenue growth assumption on Valuation.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Elevated risk of a next-quarter earnings miss: this name is on a run of consecutive earnings misses and has been missing across recent quarters. A fundamental tilt, not a price call.
Model as of 2026-09-04 · Compared with 88 industry peers · Company calendar date is not available
BJDX — private placement
Dated 2026-06-08
Entry into a Material Definitive Agreement. On June 2, 2026, Bluejay Diagnostics, Inc. (the “Company”), in connection with a private placement of the Company’s securities, entered into with certain institutional, accredited investors (i) a securities purchase agreement, and (ii) a registration rights agreement (the “private placement”). The private placement closed on June 5, 2026. Pursuant to the purchase agreement, the Company offered and sold (i) pre-funded warrants to purchase up to 3,655…
Why it matters: Watching cash burn is important for understanding financial health. High burn may mean trouble.
Worry ifCash burn rate reported in Q3 is lower than $1.5 million per month.
Less concerning ifCash burn rate goes over $1.5 million each month, showing worse financial conditions.
Why it matters: It is important to understand cash burn trends. This helps assess financial health.
Worry ifCash burn has decreased a lot. This shows better cost management than before.
Less concerning ifCash burn is still high or rising. This shows ongoing financial challenges.
Why it matters: This funding is important. It helps extend cash runway and supports FDA approval efforts.
Supportive ifThe private placement has closed. Funds have been received as planned.
Worry ifDelays or issues in closing the private placement that impact cash flow.
Why it matters: Data analysis will show how well the Symphony IL-6 test works. This is important for future regulatory steps.
Supportive ifThe company says that data analysis from the SYMON-II study is done.
Worry ifThe company says there are delays or problems in data analysis. This suggests issues with the study.
Why it matters: This partnership will help make products. This is key for future sales.
Supportive ifThey have reached important goals. This is for making products in the U.S.
Worry ifThere are reports of delays. These challenges slow down manufacturing progress.
Why it matters: The results will show if the Symphony IL-6 test can predict sepsis death. Good results could help with regulatory approval and selling the product.
Supportive ifResults from the SYMON-II study show a strong link between IL-6 levels and 28-day death risk.
Worry ifResults do not show a strong link, raising doubts about the test's usefulness.
Why it matters: Progress on this deal is important. It helps Bluejay grow its manufacturing and support expansion.
Supportive ifThere is news about reaching important goals under the Argonaut deal.
Worry ifNo news or delays have been reported about the Argonaut deal.
Why it matters: Getting at least $20 million is important for paying for operations and the FDA submission.
Supportive ifAn announcement of a successful capital raise or new funding round.
Worry ifNo new funding announcements or indications of cash flow issues.
Why it matters: The cash runway affects how the company funds its work. It shows financial health.
Supportive ifCash runway may last beyond the second quarter of 2027. This is due to successful warrant exercises.
Worry ifCash runway updates may show funding problems or not enough money raised.
Why it matters: Results will show if the IL-6 test can help predict sepsis mortality. This is key for future FDA approval.
Supportive ifA press release confirming the results of the SYMON-II study is published.
Worry ifNo results are out by the expected time. Results do not show the IL-6 test is useful.
Why it matters: Raising capital is important for Bluejay. It helps with operations and growth. It shows that investors believe in the company.
Supportive ifAnnouncement of a successful capital raise of at least $20 million by the end of 2027.
Worry ifFailure to raise the targeted $20 million by the end of 2027.
Why it matters: This submission is key for commercialization. Approval could lead to more money.
Supportive ifThe company files a 510(k) application with the FDA for the Symphony IL-6 test.
Worry ifThe company delays the FDA submission past the expected date.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$377 on $10,000 · ±3.8% | How much price usually moves either way. |
| Bad day | $1,232 loss on $10,000 · 12.3% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $9,405 loss on $10,000 · 94.0% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.